

# Expanding a Database-derived Biomedical Knowledge Graph via Multi-relation Extraction from Biomedical Abstracts

A DOI-citable version of this manuscript is available at <https://doi.org/10.1101/730085>.

This manuscript ([permalink](#)) was automatically generated from [greenelab/text mined hetnet manuscript@1ccd3b6](#) on April 25, 2022.

## Authors

---

- **David N. Nicholson**

 [0000-0003-0002-5761](#) ·  [danich1](#)

Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania · Funded by GBMF4552

- **Daniel S. Himmelstein**

 [0000-0002-3012-7446](#) ·  [dhimmel](#) ·  [dhimmel](#)

Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania · Funded by GBMF4552

- **Casey S. Greene**

 [0000-0001-8713-9213](#) ·  [cgreene](#) ·  [GreeneScientist](#)

Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania · Funded by GBMF4552 and R01 HG010067

# Abstract

---

Knowledge graphs support multiple research efforts by providing contextual information for biomedical entities, constructing networks, and supporting the interpretation of high-throughput analyses. These databases are populated via some form of manual curation, which is difficult to scale in the context of an increasing publication rate. Data programming is a paradigm that circumvents this arduous manual process by combining databases with simple rules and heuristics written as label functions, which are programs designed to automatically annotate textual data. Unfortunately, writing a useful label function requires substantial error analysis and is a nontrivial task that takes multiple days per function. This makes populating a knowledge graph with multiple nodes and edge types practically infeasible. We sought to accelerate the label function creation process by evaluating the extent to which label functions could be re-used across multiple edge types. We used a subset of an existing knowledge graph centered on disease, compound, and gene entities to evaluate label function re-use. We determined the best label function combination by comparing a baseline database-only model with the same model but added edge-specific or edge-mismatch label functions. We confirmed that adding additional edge-specific rather than edge-mismatch label functions often improves text annotation and shows that this approach can incorporate novel edges into our source knowledge graph. We expect that continued development of this strategy has the potential to swiftly populate knowledge graphs with new discoveries, ensuring that these resources include cutting-edge results.

## Introduction

---

Knowledge bases are essential resources that hold complex structured and unstructured information. These resources have been used to construct networks for drug repurposing discovery [1,2,3] or as a source of training labels for text mining systems [4,5,6]. Populating knowledge bases often requires highly trained scientists to read biomedical literature and summarize the results through manual curation [7]. In 2007, researchers estimated that filling a knowledge base via manual curation would require approximately 8.4 years to complete [8]. As the rate of publications increases exponentially [9], using only manual curation to populate a knowledge base has become nearly impractical.

Relationship extraction is one of several solutions to the challenge posed by an exponentially growing body of literature [7]. This process creates an expert system to automatically scan, detect, and extract relationships from textual sources. These expert systems fall into three types: unsupervised, rule-based, and supervised systems.

Unsupervised systems extract relationships without the need for annotated text. These approaches utilize linguistic patterns such as the frequency of two entities appearing in a sentence together more often than chance, commonly referred to as co-occurrence [10,11,12,13,14,15,16,17,18]. For example, a possible system would say gene X is associated with disease Y because gene X and disease Y appear together more often than chance [10]. Besides frequency, other systems can utilize grammatical structure to identify relationships [19]. This information is modeled in the form of a tree data structure, termed a dependency tree. Dependency trees depict words as nodes, and edges represent a word's grammatical relationship with one another. Through clustering on these generated trees, one can identify patterns that indicate a biomedical relationship [19]. Unsupervised systems are desirable since they do not require well-annotated training data; however, precision may be limited compared to supervised machine learning systems.

Rule-based systems rely heavily on expert knowledge to perform relationship extraction. These systems use linguistic rules and heuristics to identify critical sentences or phrases that suggest the presence of a biomedical relationship [20,21,22,23,24,25]. For example, a hypothetical extractor

focused on protein phosphorylation events would identify sentences containing the phrase “gene X phosphorylates gene Y” [20]. These approaches provide exact results, but the quantity of positive results remains modest as sentences consistently change in form and structure. For this project, we constructed our label functions without the aid of these works; however, the approaches mentioned in this section provide substantial inspiration for novel label functions in future endeavors.

Supervised systems depend on machine learning classifiers to predict the existence of a relationship using biomedical text as input. These classifiers can range from linear methods such as support vector machines [26,27] to deep learning [28,29,30,31,32,33], which all require access to well-annotated datasets. Typically, these datasets are usually constructed via manual curation by individual scientists [34,35,36,37,38] or through community-based efforts [39,40,41]. Often, these datasets are well annotated but are modest in size, making model training hard as these algorithms become increasingly complex.

Distant supervision is a paradigm that quickly sidesteps manual curation to generate large training datasets. This technique assumes that positive examples have been previously established in selected databases, implying that the corresponding sentences or data points are also positive [4]. The central problem with this technique is that generated labels are often of low quality, resulting in many false positives [42]. Despite this caveat there have been notable effort using this technique [43,44,45].

Data programming is one proposed solution to amend the false positive problem in distant supervision. This strategy combines labels obtained from distant supervision with simple rules and heuristics written as small programs called label functions [46]. These outputs are consolidated via a noise-aware model to produce training labels for large datasets. Using this paradigm can dramatically reduce the time required to obtain sufficient training data; however, writing a helpful label function requires substantial time and error analysis. This dependency makes constructing a knowledge base with a myriad of heterogenous relationships nearly impossible as tens or hundreds of label functions are necessary per relationship type.


This paper seeks to accelerate the label function creation process by measuring how label functions can be reused across different relationship types. We hypothesized that sentences describing one relationship type might share linguistic features such as keywords or sentence structure with sentences describing other relationship types. If this hypothesis were to, one could drastically reduce the time needed to build a relation extractor system and swiftly populate large databases like Hetionet v1. We conducted a series of experiments to estimate how label function reuse enhances performance over distant supervision alone. We focused on relationships that indicated similar types of physical interactions (i.e., gene-binds-gene and compound-binds-gene) and two more distinct types (i.e., disease-associates-gene and compound-treats-disease).

## Methods and Materials

---

### Hetionet

Hetionet v1 [3] is a heterogeneous network that contains pharmacological and biological information. This network depicts information in the form of nodes and edges of different types. Nodes in this network represent biological and pharmacological entities, while edges represent relationships between entities. Hetionet v1 contains 47,031 nodes with 11 different data types and 2,250,197 edges that represent 24 different relationship types (Figure 1). Edges in Hetionet v1 were obtained from open databases, such as the GWAS Catalog [47], Human Interaction database [48] and DrugBank [49]. For this project, we analyzed performance over a subset of the Hetionet v1 edge types: disease associates with a gene (DaG), compound binds to a gene (CbG), compound treating a disease (CtD), and gene interacts with gene (GiG) (bolded in Figure 1).



**Figure 1:** A metagraph (schema) of Hetionet v1 where biomedical entities are represented as nodes and the relationships between them are represented as edges. We examined performance on the highlighted subgraph; however, the long-term vision is to capture edges for the entire graph.

## Dataset

We used PubTator Central [50] as input to our analysis. PubTator Central provides MEDLINE abstracts that have been annotated with well-established entity recognition tools including Tagger One [51] for disease, chemical and cell line entities, tmVar [52] for genetic variation tagging, GNormPlus [53] for gene entities and SR4GN [54] for species entities. We downloaded PubTator Central on March 1, 2020, at which point it contained approximately 30,000,000 documents. After downloading, we filtered out annotated entities that were not contained in Hetionet v1. We extracted sentences with two or more annotations and termed these sentences as candidate sentences. We used the Spacy’s English natural language processing (NLP) pipeline (en\_core\_web\_sm) [55] to generate dependency trees and parts of speech tags for every extracted candidate sentence. Each candidate sentence was stratified by their corresponding abstract ID to produce a training set, tuning set, and a testing set. We used random assortment to assign dataset labels to each abstract. Every abstract had a 70% chance of being labeled training, 20% chance of being labeled tuning, and 10% chance of being labeled testing. Despite the power of data programming, all text mining systems need to have ground truth labels to be well-calibrated. We hand-labeled five hundred to a thousand candidate sentences of each edge type to obtain a ground truth set (Table 1).

**Table 1:** Statistics of Candidate Sentences. We sorted each abstract into a training, tuning and testing set. Numbers in parentheses show the number of positives and negatives that resulted from the hand-labeling process.

| Relationship            | Train  | Tune              | Test              |
|-------------------------|--------|-------------------|-------------------|
| Disease Associates Gene | 2.49 M | 696K (397+, 603-) | 348K (351+, 649-) |

| Relationship            | Train | Tune              | Test              |
|-------------------------|-------|-------------------|-------------------|
| Compound Binds Gene     | 2.4M  | 684K (37+, 463-)  | 341k (31+, 469-)  |
| Compound Treats Disease | 1.5M  | 441K (96+, 404-)  | 223K (112+, 388-) |
| Gene Interacts Gene     | 11.2M | 2.19M (60+, 440-) | 1.62M (76+, 424-) |

## Label Functions for Annotating Sentences

The challenge of having too few ground truth annotations is familiar to many natural language processing applications, even when unannotated text is abundant. Data programming circumvents this issue by quickly annotating large datasets using multiple noisy signals emitted by label functions [46]. Label functions are simple pythonic functions that emit: a positive label (1), a negative label (0), or abstain from emitting a label (-1). These functions can use different approaches or techniques to emit a label; however, these functions can be grouped into simple categories discussed below. Once constructed, these functions are combined using a generative model to output a single annotation. This single annotation is a consensus probability score bounded between 0 (low chance of mentioning a relationship) and 1 (high chance of mentioning a relationship). We used these annotations to train a discriminative model for the final classification step.

## Label Function Categories

Label functions can be constructed in various ways; however, they also share similar characteristics. We grouped functions into databases and text patterns. The majority of our label functions fall into the text pattern category (Supplemental Table 2). Further, we described each label function category and provided an example that refers to the following candidate sentence: “**PTK6** may be a novel therapeutic target for **pancreatic cancer**”.

**Databases:** These label functions incorporate existing databases to generate a signal, as seen in distant supervision [4]. These functions detect if a candidate sentence’s co-mention pair is present in a given database. Our label function emits a positive label if the pair is present and abstains otherwise. If the pair is not present in any existing database, a separate label function emits a negative label. We used a separate label function to prevent a label imbalance problem, which can occur when a single function labels every possible sentence despite being correct or not. If this problem isn’t handled correctly, the generative model could become biased and only emit one prediction (solely positive or solely negative) for every sentence.

$$\Lambda_{DB}(D, G) = \begin{cases} 1 & (D, G) \in DB \\ 0 & otherwise \end{cases}$$

$$\Lambda_{\neg DB}(D, G) = \begin{cases} -1 & (D, G) \notin DB \\ 0 & otherwise \end{cases}$$

**Text Patterns:** These label functions are designed to use keywords or sentence context to generate a signal. For example, a label function could focus on the number of words between two mentions and emit a label if two mentions are too close. Alternatively, a label function could focus on the parts of speech contained within a sentence and ensures a verb is present. Besides parts of speech, a label function could exploit dependency parse trees to emit a label. These trees are akin to the tree data structure where words are nodes and edges are how each word modifies each other. Label functions that use these parse trees will test if the generated tree matches a pattern and emits a positive label if true. For our analysis, we used previously identified patterns designed for biomedical text to generate our label functions [tag:global\_network?].

$$\Lambda_{TP}(D, G) = \begin{cases} 1 & \text{"target" } \in \text{Candidate Sentence} \\ -1 & \text{otherwise} \end{cases}$$

$$\Lambda_{TP}(D, G) = \begin{cases} 0 & \text{"VB" } \notin \text{pos\_tags(Candidate Sentence)} \\ -1 & \text{otherwise} \end{cases}$$

$$\Lambda_{TP}(D, G) = \begin{cases} 1 & \text{dep(Candidate Sentence)} \in \text{Cluster Theme} \\ -1 & \text{otherwise} \end{cases}$$

Each text pattern label function was constructed via manual examination of sentences within the training set. For example, using the candidate sentence above, one would identify the phrase “novel therapeutic target” and incorporate this phrase into a global list that a label function would use to check if present in a sentence. After initial construction, we tested and augmented the label function using sentences in the tune set. We repeated this process for every label function in our repertoire.

**Table 2:** The distribution of each label function per relationship.

| Relationship | Databases (DB) | Text Patterns (TP) |  |
|--------------|----------------|--------------------|--|
| DaG          | 7              | 30                 |  |
| CtD          | 3              | 22                 |  |
| CbG          | 9              | 20                 |  |
| GiG          | 9              | 28                 |  |

## Training Models

### Generative Model

The generative model is a core part of this automatic annotation framework. It integrates multiple signals emitted by label functions to assign each candidate sentence the most appropriate training class. This model takes as input a label function output in the form of a matrix where rows represent candidate sentences, and columns represent each label function ( $\Lambda^{n \times m}$ ). Once constructed, this model treats the true training class ( $Y$ ) as a latent variable and assumes that each label function is independent of one another. Under these two assumptions, the model finds the optimal parameters by minimizing a loglikelihood function marginalized over the latent training class.

$$\hat{\theta} = \underset{\theta}{\operatorname{argmin}} \sum_Y -\log(P_{\theta}(\Lambda, Y))$$

Following optimization, the model emits a probability estimate that each sentence belongs to the positive training class. At this step, each probability estimate can be discretized via a chosen threshold into a positive or negative class. We used a threshold of 0.5 for discretizing our training classes within our analysis. For more information on how the likelihood function is constructed and minimized, refer to [56].

### Discriminative Model

The discriminative model is the final step in this framework. This model uses training labels generated from the generative model combined with sentence features to classify the presence of a biomedical relationship. Typically, the discriminative model is a neural network. We used BioBERT [31], a BERT



[57] model trained on all papers and abstracts within Pubmed Central [58], as our discriminative model. BioBERT provides its own set of word embeddings, dense vectors representing words that models such as neural networks can use to construct sentence features. We downloaded a pre-trained version of this model using huggingface's transformer python package [59] and fine-tuned it using our generated training labels. Our fine-tuning approach involved freezing all downstream layers except for the classification head of this model. Next, we trained this model for 10 epochs using the Adam optimizer [60] with huggingface's default parameter settings and a learning rate of 0.001.

## Experimental Design


Reusing label functions across edge types would substantially reduce the number of label functions required to extract multiple relationships from biomedical literature. We first established a baseline by training a generative model using only distant supervision label functions designed for the target edge type (see Supplemental Methods). Then we compared the baseline model with models that incorporated a set number of text pattern label functions. Using a sampling with replacement approach, we sampled these text pattern label functions from three different groups: within edge types, across edge types, and from a pool of all label functions. We compared within-edge-type performance to across-edge-type and all-edge-type performance. We sampled a fixed number of label functions for each edge type consisting of five evenly spaced numbers between one and the total number of possible label functions. We repeated this sampling process 50 times for each point. Furthermore, we also trained the discriminative model using annotations from the generative model trained on edge-specific label functions at each point. We report the performance of both models in terms of the area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPR). Ensuing model evaluations, we quantified the number of edges we could incorporate into Hetionet v1. We used our best performing discriminative model to score every candidate sentence within our dataset and grouped candidates based on their mention pair. We took the max score within each candidate group, and this score represents the probability of the existence of an edge. We established edges using a cutoff score that produced an equal error rate between the false positives and false negatives. Lastly, we report the number of preexisting edges we could recall and the number of novel edges we can incorporate.

## Results

---

### Generative Model Using Randomly Sampled Label Functions

Creating label functions is a labor-intensive process that can take days to accomplish. We sought to accelerate this process by measuring how well label functions can be reused. We evaluated this by performing an experiment where label functions are sampled on an individual (edge vs. edge) level and a global (collective pool of sources) level. We observed that performance increased when edge-specific label functions were added to an edge-specific baseline model, while label function reuse usually provided less benefit (AUROC Figure 2, AUPR Supplemental Figure 6). The quintessential example of this overarching trend is the Compound-treats-Disease (CtD) edge type, where edge-specific label functions consistently outperformed transferred label functions. However, there is evidence that label function transferability may be feasible for selected edge types and label function sources. Performance increases as more Gene-interacts-Gene (GiG) label functions are incorporated into the Compound-binds-Gene (CbG) baseline model and vice versa. This trend suggests that sentences for GiG and CbG may share similar linguistic features or terminology that allows for label functions to be reused, which could relate to both describing physical interaction relationships. Perplexingly, edge-specific Disease-associates-Gene (DaG) label functions did not improve performance over label functions drawn from other edge types. Overall, only CbG and GiG showed significant signs of reusability. This pattern suggests that label function transferability may be possible for these two edge types.




**Figure 2:** Edge-specific label functions perform better than edge-mismatch label functions, but certain mismatch situations show signs of successful transfer. Each line plot header depicts the edge type the generative model is trying to predict, while the colors represent the source of label functions. For example, orange represents sampling label functions designed to predict the Compound-treats-Disease (CtD) edge type. The x-axis shows the number of randomly sampled label functions incorporated as an addition to the database-only baseline model (the point at 0). The y-axis shows the area under the receiver operating curve (AUROC). Each point on the plot shows the average of 50 sample runs, while the error bars show the 95% confidence intervals of all runs. The baseline and “All” data points consist of sampling from the entire fixed set of label functions.

We found that sampling from all label function sources at once usually underperformed relative to edge-specific label functions (Figure 3 and Supplemental Figure 7). The gap between edge-specific sources and all sources widened as we sampled more label functions. CbG is a prime example of this trend (Figure 3 and Supplemental Figure 7), while CtD and GiG show a similar but milder trend. DaG was the exception to the general rule. The pooled set of label functions improved performance over the edge-specific ones, which aligns with the previously observed results for individual edge types (Figure 2). When pooling all label functions, the decreasing trend supports the notion that label functions cannot simply transfer between edge types (exception being CbG on GiG and vice versa).




## Generative Model Performance using All Label Functions (Test Set/AUROC)



**Figure 3:** Using all label functions generally hinders generative model performance. Each line plot header depicts the edge type the generative model is trying to predict, while the colors represent the source of label functions. For example, orange represents sampling label functions designed to predict the Compound-treats-Disease (CtD) edge type. The x-axis shows the number of randomly sampled label functions incorporated as an addition to the database-only baseline model (the point at 0). The y-axis shows the area under the receiver operating curve (AUROC). Each point on the plot shows the average of 50 sample runs, while the error bars show the 95% confidence intervals of all runs. The baseline and “All” data points consist of sampling from the entire fixed set of label functions.


## Discriminative Model Performance

The discriminative model is intended to augment performance over the generative model by incorporating textual features together with estimated training labels. We found that the discriminative model generally outperformed the generative model with respect to AUROC as more edge-specific label functions were incorporated (Figure 4). Regarding AUPR, this model outperformed the generative model for the Disease-associates-Gene (DaG) edge type. At the same time, it had close to par performance for the rest of the edge types (Supplemental Figure 8). The discriminative model's performance was often poorest when very few edge-specific label functions were incorporated into the baseline model (seen in DaG, CbG, and Gene-interacts-Gene (GiG)). This example suggests that training generative models with more label functions produces better outputs for training for discriminative models. Compound-treats-Disease (CtD) was an exception to this trend, where the discriminative model outperformed the generative model at all sampling levels in regards to AUROC. We observed the opposite trend with the Compound-binds-Gene (CbG) edges as the discriminative model was always worse or indistinguishable from the generative model. Interestingly, the AUPR for CbG plateaus below the generative model and decreases when all edge-specific label functions are used (Supplemental Figure 8). This trend suggests that the discriminative model might have predicted more false positives in this setting. Overall, incorporating more edge-specific label functions usually improved performance for the discriminative model over the generative model.



**Figure 4:** The discriminative model usually improves faster than the generative model as more edge-specific label functions are included. The line plot headers represent the specific edge type the discriminative model is trying to predict. The x-axis shows the number of randomly sampled label functions incorporated as an addition to the baseline model (the point at 0). The y axis shows the area under the receiver operating curve (AUROC). Each data point represents the average of 3 sample runs for the discriminator model and 50 sample runs for the generative model. The error bars represent each run's 95% confidence interval. The baseline and "All" data points consist of sampling from the entire fixed set of label functions.

## Text Mined Edges Can Expand a Database-derived Knowledge Graph



**Figure 5:** Text-mined edges recreate a substantial fraction of an existing knowledge graph and include new predictions. This bar chart shows the number of edges we can successfully recall in green and indicates the number of new edges in blue.

The recall for the Hetionet v1 knowledge graph is shown as a percentage in parentheses. For example, for the Compound-treats-Disease (CtD) edge, our method recalls 30% of existing edges and can add 6,282 new ones.

One of the goals of our work is to measure the extent to which learning multiple edge types could construct a biomedical knowledge graph. Using Hetionet v1 as an evaluation set, we measured this framework's recall and quantified the number of edges that may be incorporated with high confidence. Overall, we were able to recall about thirty percent of the preexisting edges for all edge types (Figure 5) and report our top ten scoring sentences for each edge type in Supplemental Table 3. Our best recall was with the Compound-binds-Gene (CbG) edge type, where we retained 33% of preexisting edges. In contrast, we only recalled close to 30% for Compound-treats-Disease (CtD), while the other two categories achieved a recall score close to 22%. Despite the modest recall level, the amount of novel edge types remains elevated. This notion highlights that Hetionet v1 is missing a compelling amount of biomedical information, and relationship extraction is a viable way to close the information gap.

## Discussion and Conclusions

Filling out knowledge bases via manual curation can be an arduous and erroneous task [8]. Using manual curation alone becomes impractical as the rate of publications continuously increases. Data programming is a paradigm that uses label functions to speed up the annotation process and can be used to solve this problem. However, creating useful label functions is an obstacle to this paradigm, which takes considerable time. We tested the feasibility of re-using label functions to reduce the number of label functions required for strong prediction performance.

Our sampling experiment revealed that adding edge-specific label functions is better than adding off-edge label functions. An exception to this trend is using label functions designed from conceptually related edge types (using Gene-interacts-Gene (GiG) label functions to predict Compound-binds-Gene (CbG) sentences and vice versa). Furthermore, broad edge types such as Disease-associates-Gene (DaG) did not follow this trend as we found this edge to be agnostic to any tested label function source. One possibility for this observation is that the “associates” relationship is a general concept that may include other concepts such as Disease (up/down) regulating a Gene (examples highlighted in our [annotated sentences](#)). The discriminator model did not have an apparent positive or negative effect on performance; however, we noticed that performance heavily depended on the annotations provided by the generative model. This pattern suggests a focus on label function construction and generative model training may be key steps to focus on in future work. Although we found that label functions cannot be re-used across all edge types with the standard task framing, strategies like multitask [61] or transfer learning [62] may make multi-label-function efforts more successful.

## Supplemental Information

---

An online version of this manuscript is available at [https://greenelab.github.io/text\\_mined\\_hetnet\\_manuscript/](https://greenelab.github.io/text_mined_hetnet_manuscript/). Labeled sentences are available at [https://github.com/greenelab/text\\_mined\\_hetnet\\_manuscript/tree/master/supplementary\\_materials/annotated\\_sentences](https://github.com/greenelab/text_mined_hetnet_manuscript/tree/master/supplementary_materials/annotated_sentences). Source code for this work is available under open licenses at: <https://github.com/greenelab/snorkeling/>.

## Acknowledgements

---

The authors would like to thank Christopher Ré’s group at Stanford University, especially Alex Ratner and Steven Bach, for their assistance with this project. We also want to thank Graciela Gonzalez-Hernandez for her advice and input with this project. This work was supported by [Grant GBMF4552](#) from the Gordon Betty Moore Foundation.

# References

---

1. **Graph Theory Enables Drug Repurposing – How a Mathematical Model Can Drive the Discovery of Hidden Mechanisms of Action**  
Ruggero Gramatica, T Di Matteo, Stefano Giorgetti, Massimo Barbiani, Dorian Bevec, Tomaso Aste  
*PLoS ONE* (2014-01-09) <https://doi.org/gf45zp>  
DOI: [10.1371/journal.pone.0084912](https://doi.org/10.1371/journal.pone.0084912) · PMID: [24416311](https://pubmed.ncbi.nlm.nih.gov/24416311/) · PMCID: [PMC3886994](https://pubmed.ncbi.nlm.nih.gov/PMC3886994/)
2. **Drug repurposing through joint learning on knowledge graphs and literature**  
Mona Alshahrani, Robert Hoehndorf  
*Bioinformatics* (2018-08-06) <https://doi.org/gf45zk>  
DOI: [10.1101/385617](https://doi.org/10.1101/385617)
3. **Systematic integration of biomedical knowledge prioritizes drugs for repurposing**  
Daniel Scott Himmelstein, Antoine Lizee, Christine Hessler, Leo Brueggeman, Sabrina L Chen, Dexter Hadley, Ari Green, Pouya Khankhanian, Sergio E Baranzini  
*eLife* (2017-09-22) <https://doi.org/cdfk>  
DOI: [10.7554/elife.26726](https://doi.org/10.7554/elife.26726) · PMID: [28936969](https://pubmed.ncbi.nlm.nih.gov/28936969/) · PMCID: [PMC5640425](https://pubmed.ncbi.nlm.nih.gov/PMC5640425/)
4. **Distant supervision for relation extraction without labeled data**  
Mike Mintz, Steven Bills, Rion Snow, Dan Jurafsky  
*Proceedings of the Joint Conference of the 47th Annual Meeting of the ACL and the 4th International Joint Conference on Natural Language Processing of the AFNLP: Volume 2 - ACL-IJCNLP '09* (2009) <https://doi.org/fg9q43>  
DOI: [10.3115/1690219.1690287](https://doi.org/10.3115/1690219.1690287) · ISBN: 9781932432466
5. **CoCoScore: Context-aware co-occurrence scoring for text mining applications using distant supervision**  
Alexander Junge, Lars Juhl Jensen  
*Bioinformatics* (2018-10-16) <https://doi.org/gf45zm>  
DOI: [10.1101/444398](https://doi.org/10.1101/444398)
6. **Knowledge-guided convolutional networks for chemical-disease relation extraction**  
Huiwei Zhou, Chengkun Lang, Zhuang Liu, Shixian Ning, Yingyu Lin, Lei Du  
*BMC Bioinformatics* (2019-12) <https://doi.org/gf45zn>  
DOI: [10.1186/s12859-019-2873-7](https://doi.org/10.1186/s12859-019-2873-7) · PMID: [31113357](https://pubmed.ncbi.nlm.nih.gov/31113357/) · PMCID: [PMC6528333](https://pubmed.ncbi.nlm.nih.gov/PMC6528333/)
7. **Facts from text: can text mining help to scale-up high-quality manual curation of gene products with ontologies?**  
R Winnenburger, T Wachter, C Plake, A Doms, M Schroeder  
*Briefings in Bioinformatics* (2008-07-11) <https://doi.org/bfsnwg>  
DOI: [10.1093/bib/bbn043](https://doi.org/10.1093/bib/bbn043) · PMID: [19060303](https://pubmed.ncbi.nlm.nih.gov/19060303/)
8. **Manual curation is not sufficient for annotation of genomic databases**  
William A Baumgartner, KBretonnel Cohen, Lynne M Fox, George Acquah-Mensah, Lawrence Hunter  
*Bioinformatics* (2007-07-01) <https://doi.org/dtck86>  
DOI: [10.1093/bioinformatics/btm229](https://doi.org/10.1093/bioinformatics/btm229) · PMID: [17646325](https://pubmed.ncbi.nlm.nih.gov/17646325/) · PMCID: [PMC2516305](https://pubmed.ncbi.nlm.nih.gov/PMC2516305/)
9. **Growth rates of modern science: A bibliometric analysis based on the number of publications and cited references: Growth Rates of Modern Science: A Bibliometric Analysis Based on the Number of Publications and Cited References**  
Lutz Bornmann, Rüdiger Mutz

10. **DISEASES: Text mining and data integration of disease-gene associations**  
Sune Pletscher-Frankild, Albert Pallejà, Kalliopi Tsafou, Janos X Binder, Lars Juhl Jensen  
*Methods* (2015-03) <https://doi.org/f3mn6s>  
DOI: [10.1016/j.ymeth.2014.11.020](https://doi.org/10.1016/j.ymeth.2014.11.020) · PMID: [25484339](https://pubmed.ncbi.nlm.nih.gov/25484339/)
11. **PolySearch2: a significantly improved text-mining system for discovering associations between human diseases, genes, drugs, metabolites, toxins and more**  
Yifeng Liu, Yongjie Liang, David Wishart  
*Nucleic Acids Research* (2015-07-01) <https://doi.org/f7nzn5>  
DOI: [10.1093/nar/gkv383](https://doi.org/10.1093/nar/gkv383) · PMID: [25925572](https://pubmed.ncbi.nlm.nih.gov/25925572/) · PMCID: [PMC4489268](https://pubmed.ncbi.nlm.nih.gov/PMC4489268/)
12. **The research on gene-disease association based on text-mining of PubMed**  
Jie Zhou, Bo-quan Fu  
*BMC Bioinformatics* (2018-12) <https://doi.org/gf479k>  
DOI: [10.1186/s12859-018-2048-y](https://doi.org/10.1186/s12859-018-2048-y) · PMID: [29415654](https://pubmed.ncbi.nlm.nih.gov/29415654/) · PMCID: [PMC5804013](https://pubmed.ncbi.nlm.nih.gov/PMC5804013/)
13. **A comprehensive and quantitative comparison of text-mining in 15 million full-text articles versus their corresponding abstracts**  
David Westergaard, Hans-Henrik Stærfeldt, Christian Tønsberg, Lars Juhl Jensen, Søren Brunak  
*PLOS Computational Biology* (2018-02-15) <https://doi.org/gcx747>  
DOI: [10.1371/journal.pcbi.1005962](https://doi.org/10.1371/journal.pcbi.1005962) · PMID: [29447159](https://pubmed.ncbi.nlm.nih.gov/29447159/) · PMCID: [PMC5831415](https://pubmed.ncbi.nlm.nih.gov/PMC5831415/)
14. **Literature Mining for the Discovery of Hidden Connections between Drugs, Genes and Diseases**  
Raoul Frijters, Marianne van Vugt, Ruben Smeets, René van Schaik, Jacob de Vlieg, Wynand Alkema  
*PLoS Computational Biology* (2010-09-23) <https://doi.org/bhrw7x>  
DOI: [10.1371/journal.pcbi.1000943](https://doi.org/10.1371/journal.pcbi.1000943) · PMID: [20885778](https://pubmed.ncbi.nlm.nih.gov/20885778/) · PMCID: [PMC2944780](https://pubmed.ncbi.nlm.nih.gov/PMC2944780/)
15. **Analyzing a co-occurrence gene-interaction network to identify disease-gene association**  
Amira Al-Aamri, Kamal Taha, Yousof Al-Hammadi, Maher Maalouf, Dirar Homouz  
*BMC Bioinformatics* (2019-12) <https://doi.org/gf49nm>  
DOI: [doi:10.1186/s12859-019-2634-7](https://doi.org/10.1186/s12859-019-2634-7)
16. **COMPARTMENTS: unification and visualization of protein subcellular localization evidence**  
JX Binder, S Pletscher-Frankild, K Tsafou, C Stolte, SI O'Donoghue, R Schneider, LJ Jensen  
*Database* (2014-02-25) <https://doi.org/btbm>  
DOI: [10.1093/database/bau012](https://doi.org/10.1093/database/bau012) · PMID: [24573882](https://pubmed.ncbi.nlm.nih.gov/24573882/) · PMCID: [PMC3935310](https://pubmed.ncbi.nlm.nih.gov/PMC3935310/)
17. **A new method for prioritizing drug repositioning candidates extracted by literature-based discovery**  
Majid Rastegar-Mojarad, Ravikumar Komandur Elayavilli, Dingcheng Li, Rashmi Prasad, Hongfang Liu  
*2015 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)* (2015-11) <https://doi.org/gf479j>  
DOI: [10.1109/bibm.2015.7359766](https://doi.org/10.1109/bibm.2015.7359766) · ISBN: 9781467367998
18. **Comprehensive comparison of large-scale tissue expression datasets**  
Alberto Santos, Kalliopi Tsafou, Christian Stolte, Sune Pletscher-Frankild, Seán I O'Donoghue, Lars Juhl Jensen



PeerJ (2015-06-30) <https://doi.org/f3mn6p>  
DOI: [10.7717/peerj.1054](https://doi.org/10.7717/peerj.1054) · PMID: [26157623](https://pubmed.ncbi.nlm.nih.gov/26157623/) · PMCID: [PMC4493645](https://pubmed.ncbi.nlm.nih.gov/PMC4493645/)

19. **A global network of biomedical relationships derived from text**  
Bethany Percha, Russ B Altman  
*Bioinformatics* (2018-08-01) <https://doi.org/gc3ndk>  
DOI: [10.1093/bioinformatics/bty114](https://doi.org/10.1093/bioinformatics/bty114) · PMID: [29490008](https://pubmed.ncbi.nlm.nih.gov/29490008/) · PMCID: [PMC6061699](https://pubmed.ncbi.nlm.nih.gov/PMC6061699/)
20. **RLIMS-P 2.0: A Generalizable Rule-Based Information Extraction System for Literature Mining of Protein Phosphorylation Information**  
Manabu Torii, Cecilia N Arighi, Gang Li, Qinghua Wang, Cathy H Wu, K Vijay-Shanker  
*IEEE/ACM Transactions on Computational Biology and Bioinformatics* (2015-01-01)  
<https://doi.org/gf8fpv>  
DOI: [10.1109/tcbb.2014.2372765](https://doi.org/10.1109/tcbb.2014.2372765) · PMID: [26357075](https://pubmed.ncbi.nlm.nih.gov/26357075/) · PMCID: [PMC4568560](https://pubmed.ncbi.nlm.nih.gov/PMC4568560/)
21. **Large-scale extraction of accurate drug-disease treatment pairs from biomedical literature for drug repurposing**  
Rong Xu, QuanQiu Wang  
*BMC Bioinformatics* (2013-12) <https://doi.org/gb8v3k>  
DOI: [10.1186/1471-2105-14-181](https://doi.org/10.1186/1471-2105-14-181) · PMID: [23742147](https://pubmed.ncbi.nlm.nih.gov/23742147/) · PMCID: [PMC3702428](https://pubmed.ncbi.nlm.nih.gov/PMC3702428/)
22. **Pharmspresso: a text mining tool for extraction of pharmacogenomic concepts and relationships from full text**  
Yael Garten, Russ B Altman  
*BMC Bioinformatics* (2009-02) <https://doi.org/df75hq>  
DOI: [10.1186/1471-2105-10-s2-s6](https://doi.org/10.1186/1471-2105-10-s2-s6) · PMID: [19208194](https://pubmed.ncbi.nlm.nih.gov/19208194/) · PMCID: [PMC2646239](https://pubmed.ncbi.nlm.nih.gov/PMC2646239/)
23. **LimTox: a web tool for applied text mining of adverse event and toxicity associations of compounds, drugs and genes**  
Andres Cañada, Salvador Capella-Gutierrez, Obdulia Rabal, Julen Oyarzabal, Alfonso Valencia, Martin Krallinger  
*Nucleic Acids Research* (2017-07-03) <https://doi.org/gf479h>  
DOI: [10.1093/nar/gkx462](https://doi.org/10.1093/nar/gkx462) · PMID: [28531339](https://pubmed.ncbi.nlm.nih.gov/28531339/) · PMCID: [PMC5570141](https://pubmed.ncbi.nlm.nih.gov/PMC5570141/)
24. **PPInterFinder—a mining tool for extracting causal relations on human proteins from literature**  
Kalpana Raja, Suresh Subramani, Jeyakumar Natarajan  
*Database* (2013-01-01) <https://doi.org/gf479b>  
DOI: [10.1093/database/bas052](https://doi.org/10.1093/database/bas052) · PMID: [23325628](https://pubmed.ncbi.nlm.nih.gov/23325628/) · PMCID: [PMC3548331](https://pubmed.ncbi.nlm.nih.gov/PMC3548331/)
25. **PKDE4J: Entity and relation extraction for public knowledge discovery.**  
Min Song, Won Chul Kim, Dahee Lee, Go Eun Heo, Keun Young Kang  
*Journal of biomedical informatics* (2015-08-12)  
<https://www.ncbi.nlm.nih.gov/pubmed/26277115>  
DOI: [10.1016/j.jbi.2015.08.008](https://doi.org/10.1016/j.jbi.2015.08.008) · PMID: [26277115](https://pubmed.ncbi.nlm.nih.gov/26277115/)
26. **Automatic extraction of gene-disease associations from literature using joint ensemble learning**  
Balu Bhasuran, Jeyakumar Natarajan  
*PLOS ONE* (2018-07-26) <https://doi.org/gdx63f>  
DOI: [10.1371/journal.pone.0200699](https://doi.org/10.1371/journal.pone.0200699) · PMID: [30048465](https://pubmed.ncbi.nlm.nih.gov/30048465/) · PMCID: [PMC6061985](https://pubmed.ncbi.nlm.nih.gov/PMC6061985/)
27. **DTMiner: identification of potential disease targets through biomedical literature mining**  
Dong Xu, Meizhuo Zhang, Yanping Xie, Fan Wang, Ming Chen, Kenny Q Zhu, Jia Wei  
*Bioinformatics* (2016-08-09) <https://doi.org/f9nw36>

DOI: [10.1093/bioinformatics/btw503](https://doi.org/10.1093/bioinformatics/btw503) · PMID: [27506226](https://pubmed.ncbi.nlm.nih.gov/27506226/) · PMCID: [PMC5181534](https://pubmed.ncbi.nlm.nih.gov/PMC5181534/)

28. **Extracting chemical-protein relations using attention-based neural networks**  
Sijia Liu, Feichen Shen, Ravikumar Komandur Elayavilli, Yanshan Wang, Majid Rastegar-Mojarad, Vipin Chaudhary, Hongfang Liu  
*Database* (2018-01-01) <https://doi.org/gfdz8d>  
DOI: [doi:10.1093/database/bay102](https://doi.org/10.1093/database/bay102)
29. **Deep learning in neural networks: An overview**  
Jürgen Schmidhuber  
*Neural Networks* (2015-01) <https://doi.org/f6v78n>  
DOI: [10.1016/j.neunet.2014.09.003](https://doi.org/10.1016/j.neunet.2014.09.003) · PMID: [25462637](https://pubmed.ncbi.nlm.nih.gov/25462637/)
30. **Probing Biomedical Embeddings from Language Models**  
Qiao Jin, Bhuwan Dhingra, William W Cohen, Xinghua Lu  
*arXiv* (2019-04-05) <https://arxiv.org/abs/1904.02181>
31. **BioBERT: a pre-trained biomedical language representation model for biomedical text mining**  
Jinhyuk Lee, Wonjin Yoon, Sungdong Kim, Donghyeon Kim, Sunkyu Kim, Chan Ho So, Jaewoo Kang  
*arXiv* (2019-10-21) <https://arxiv.org/abs/1901.08746>  
DOI: [10.1093/bioinformatics/btz682](https://doi.org/10.1093/bioinformatics/btz682)
32. **Attention Is All You Need**  
Ashish Vaswani, Noam Shazeer, Niki Parmar, Jakob Uszkoreit, Llion Jones, Aidan N Gomez, Lukasz Kaiser, Illia Polosukhin  
*arXiv* (2017-12-07) <https://arxiv.org/abs/1706.03762>
33. **Chemical-gene relation extraction using recursive neural network**  
Sangrak Lim, Jaewoo Kang  
*Database* (2018-01-01) <https://doi.org/gdss6f>  
DOI: [10.1093/database/bay060](https://doi.org/10.1093/database/bay060) · PMID: [29961818](https://pubmed.ncbi.nlm.nih.gov/29961818/) · PMCID: [PMC6014134](https://pubmed.ncbi.nlm.nih.gov/PMC6014134/)
34. **Extraction of relations between genes and diseases from text and large-scale data analysis: implications for translational research**  
Àlex Bravo, Janet Piñero, Núria Queralt-Rosinach, Michael Rautschka, Laura I Furlong  
*BMC Bioinformatics* (2015-12) <https://doi.org/f7kn8s>  
DOI: [10.1186/s12859-015-0472-9](https://doi.org/10.1186/s12859-015-0472-9) · PMID: [25886734](https://pubmed.ncbi.nlm.nih.gov/25886734/) · PMCID: [PMC4466840](https://pubmed.ncbi.nlm.nih.gov/PMC4466840/)
35. **The EU-ADR corpus: Annotated drugs, diseases, targets, and their relationships**  
Erik M van Mulligen, Annie Fourrier-Reglat, David Gurwitz, Mariam Molokhia, Ainhua Nieto, Gianluca Trifiro, Jan A Kors, Laura I Furlong  
*Journal of Biomedical Informatics* (2012-10) <https://doi.org/f36vn6>  
DOI: [10.1016/j.jbi.2012.04.004](https://doi.org/10.1016/j.jbi.2012.04.004) · PMID: [22554700](https://pubmed.ncbi.nlm.nih.gov/22554700/)
36. **Comparative experiments on learning information extractors for proteins and their interactions**  
Razvan Bunescu, Ruifang Ge, Rohit J Kate, Edward M Marcotte, Raymond J Mooney, Arun K Ramani, Yuk Wah Wong  
*Artificial Intelligence in Medicine* (2005-02) <https://doi.org/dhztptn>  
DOI: [10.1016/j.artmed.2004.07.016](https://doi.org/10.1016/j.artmed.2004.07.016) · PMID: [15811782](https://pubmed.ncbi.nlm.nih.gov/15811782/)
37. **BioInfer: a corpus for information extraction in the biomedical domain**  
Sampo Pyysalo, Filip Ginter, Juho Heimonen, Jari Björne, Jorma Boberg, Jouni Järvinen, Tapio Salakoski

*BMC Bioinformatics* (2007-12) <https://doi.org/b7bhbc>  
DOI: [10.1186/1471-2105-8-50](https://doi.org/10.1186/1471-2105-8-50) · PMID: [17291334](https://pubmed.ncbi.nlm.nih.gov/17291334/) · PMCID: [PMC1808065](https://pubmed.ncbi.nlm.nih.gov/PMC1808065/)

38. **RelEx--Relation extraction using dependency parse trees**  
K Fundel, R Kuffner, R Zimmer  
*Bioinformatics* (2007-02-01) <https://doi.org/cz7q4d>  
DOI: [10.1093/bioinformatics/btl616](https://doi.org/10.1093/bioinformatics/btl616) · PMID: [17142812](https://pubmed.ncbi.nlm.nih.gov/17142812/)
39. **BioCreative V CDR task corpus: a resource for chemical disease relation extraction**  
Jiao Li, Yueping Sun, Robin J Johnson, Daniela Sciaky, Chih-Hsuan Wei, Robert Leaman, Allan Peter Davis, Carolyn J Mattingly, Thomas C Wieggers, Zhiyong Lu  
*Database* (2016) <https://doi.org/gf5hfw>  
DOI: [10.1093/database/baw068](https://doi.org/10.1093/database/baw068) · PMID: [27161011](https://pubmed.ncbi.nlm.nih.gov/27161011/) · PMCID: [PMC4860626](https://pubmed.ncbi.nlm.nih.gov/PMC4860626/)
40. **Overview of the biocreative vi chemical-protein interaction track**  
Martin Krallinger, Obdulia Rabal, Saber A Akhondiothers  
*Proceedings of the sixth biocreative challenge evaluation workshop* (2017)  
<https://www.semanticscholar.org/paper/Overview-of-the-BioCreative-VI-chemical-protein-Krallinger-Rabal/eed781f498b563df5a9e8a241c67d63dd1d92ad5>
41. **Comparative analysis of five protein-protein interaction corpora**  
Sampo Pyysalo, Antti Airola, Juho Heimonen, Jari Björne, Filip Ginter, Tapio Salakoski  
*BMC Bioinformatics* (2008-04) <https://doi.org/fh3df7>  
DOI: [10.1186/1471-2105-9-s3-s6](https://doi.org/10.1186/1471-2105-9-s3-s6) · PMID: [18426551](https://pubmed.ncbi.nlm.nih.gov/18426551/) · PMCID: [PMC2349296](https://pubmed.ncbi.nlm.nih.gov/PMC2349296/)
42. **Revisiting distant supervision for relation extraction**  
Tingsong Jiang, Jing Liu, Chin-Yew Lin, Zhifang Sui  
*Proceedings of the eleventh international conference on language resources and evaluation (LREC 2018)* (2018-05) <https://aclanthology.org/L18-1566>
43. **Large-scale extraction of gene interactions from full-text literature using DeepDive**  
Emily K Mallory, Ce Zhang, Christopher Ré, Russ B Altman  
*Bioinformatics* (2015-09-03) <https://doi.org/gb5g7b>  
DOI: [10.1093/bioinformatics/btv476](https://doi.org/10.1093/bioinformatics/btv476) · PMID: [26338771](https://pubmed.ncbi.nlm.nih.gov/26338771/) · PMCID: [PMC4681986](https://pubmed.ncbi.nlm.nih.gov/PMC4681986/)
44. **Distant Supervision for Large-Scale Extraction of Gene-Disease Associations from Literature Using DeepDive**  
Balu Bhasuran, Jeyakumar Natarajan  
*International Conference on Innovative Computing and Communications* (2019)  
<https://doi.org/gf5hfv>  
DOI: [10.1007/978-981-13-2354-6\\_39](https://doi.org/10.1007/978-981-13-2354-6_39) · ISBN: 9789811323539
45. **CoCoScore: context-aware co-occurrence scoring for text mining applications using distant supervision**  
Alexander Junge, Lars Juhl Jensen  
*Bioinformatics* (2020-01-01) <https://doi.org/gf4789>  
DOI: [10.1093/bioinformatics/btz490](https://doi.org/10.1093/bioinformatics/btz490) · PMID: [31199464](https://pubmed.ncbi.nlm.nih.gov/31199464/) · PMCID: [PMC6956794](https://pubmed.ncbi.nlm.nih.gov/PMC6956794/)
46. **Data Programming: Creating Large Training Sets, Quickly**  
Alexander Ratner, Christopher De Sa, Sen Wu, Daniel Selsam, Christopher Ré  
*arXiv* (2018-12-10) <https://arxiv.org/abs/1605.07723>
47. **The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog)**  
Jacqueline MacArthur, Emily Bowler, Maria Cerezo, Laurent Gil, Peggy Hall, Emma Hastings, Heather Junkins, Aoife McMahon, Annalisa Milano, Joannella Morales, ... Helen Parkinson

*Nucleic Acids Research* (2017-01-04) <https://doi.org/f9v7cp>  
DOI: [10.1093/nar/gkw1133](https://doi.org/10.1093/nar/gkw1133) · PMID: [27899670](https://pubmed.ncbi.nlm.nih.gov/27899670/) · PMCID: [PMC5210590](https://pubmed.ncbi.nlm.nih.gov/PMC5210590/)

48. **A Proteome-Scale Map of the Human Interactome Network**  
Thomas Rolland, Murat Taşan, Benoit Charlotteaux, Samuel J Pevzner, Quan Zhong, Nidhi Sahni, Song Yi, Irma Lemmens, Celia Fontanillo, Roberto Mosca, ... Marc Vidal  
*Cell* (2014-11) <https://doi.org/f3mn6x>  
DOI: [10.1016/j.cell.2014.10.050](https://doi.org/10.1016/j.cell.2014.10.050) · PMID: [25416956](https://pubmed.ncbi.nlm.nih.gov/25416956/) · PMCID: [PMC4266588](https://pubmed.ncbi.nlm.nih.gov/PMC4266588/)
49. **DrugBank 5.0: a major update to the DrugBank database for 2018**  
David S Wishart, Yannick D Feunang, An C Guo, Elvis J Lo, Ana Marcu, Jason R Grant, Tanvir Sajed, Daniel Johnson, Carin Li, Zinat Sayeeda, ... Michael Wilson  
*Nucleic Acids Research* (2018-01-04) <https://doi.org/gcwtzk>  
DOI: [10.1093/nar/gkx1037](https://doi.org/10.1093/nar/gkx1037) · PMID: [29126136](https://pubmed.ncbi.nlm.nih.gov/29126136/) · PMCID: [PMC5753335](https://pubmed.ncbi.nlm.nih.gov/PMC5753335/)
50. **PubTator central: automated concept annotation for biomedical full text articles**  
Chih-Hsuan Wei, Alexis Allot, Robert Leaman, Zhiyong Lu  
*Nucleic Acids Research* (2019-07-02) <https://doi.org/ggzfsc>  
DOI: [10.1093/nar/gkz389](https://doi.org/10.1093/nar/gkz389) · PMID: [31114887](https://pubmed.ncbi.nlm.nih.gov/31114887/) · PMCID: [PMC6602571](https://pubmed.ncbi.nlm.nih.gov/PMC6602571/)
51. **TaggerOne: joint named entity recognition and normalization with semi-Markov Models**  
Robert Leaman, Zhiyong Lu  
*Bioinformatics* (2016-09-15) <https://doi.org/f855dg>  
DOI: [10.1093/bioinformatics/btw343](https://doi.org/10.1093/bioinformatics/btw343) · PMID: [27283952](https://pubmed.ncbi.nlm.nih.gov/27283952/) · PMCID: [PMC5018376](https://pubmed.ncbi.nlm.nih.gov/PMC5018376/)
52. **tmVar 2.0: integrating genomic variant information from literature with dbSNP and ClinVar for precision medicine**  
Chih-Hsuan Wei, Lon Phan, Juliana Feltz, Rama Maiti, Tim Hefferon, Zhiyong Lu  
*Bioinformatics* (2018-01-01) <https://doi.org/gbzsmc>  
DOI: [10.1093/bioinformatics/btx541](https://doi.org/10.1093/bioinformatics/btx541) · PMID: [28968638](https://pubmed.ncbi.nlm.nih.gov/28968638/) · PMCID: [PMC5860583](https://pubmed.ncbi.nlm.nih.gov/PMC5860583/)
53. **GNormPlus: An Integrative Approach for Tagging Genes, Gene Families, and Protein Domains**  
Chih-Hsuan Wei, Hung-Yu Kao, Zhiyong Lu  
*BioMed Research International* (2015) <https://doi.org/gb85jb>  
DOI: [10.1155/2015/918710](https://doi.org/10.1155/2015/918710) · PMID: [26380306](https://pubmed.ncbi.nlm.nih.gov/26380306/) · PMCID: [PMC4561873](https://pubmed.ncbi.nlm.nih.gov/PMC4561873/)
54. **SR4GN: A Species Recognition Software Tool for Gene Normalization**  
Chih-Hsuan Wei, Hung-Yu Kao, Zhiyong Lu  
*PLoS ONE* (2012-06-05) <https://doi.org/gpq498>  
DOI: [10.1371/journal.pone.0038460](https://doi.org/10.1371/journal.pone.0038460) · PMID: [22679507](https://pubmed.ncbi.nlm.nih.gov/22679507/) · PMCID: [PMC3367953](https://pubmed.ncbi.nlm.nih.gov/PMC3367953/)
55. **spaCy 2: Natural language understanding with Bloom embeddings, convolutional neural networks and incremental parsing**  
Matthew Honnibal, Ines Montani  
(2017)
56. **Snorkel: rapid training data creation with weak supervision**  
Alexander Ratner, Stephen H Bach, Henry Ehrenberg, Jason Fries, Sen Wu, Christopher Ré  
*The VLDB Journal* (2020-05) <https://doi.org/ghbw5f>  
DOI: [10.1007/s00778-019-00552-1](https://doi.org/10.1007/s00778-019-00552-1) · PMID: [32214778](https://pubmed.ncbi.nlm.nih.gov/32214778/) · PMCID: [PMC7075849](https://pubmed.ncbi.nlm.nih.gov/PMC7075849/)
57. **[No title found]**  
Jacob Devlin, Ming-Wei Chang, Kenton Lee, Kristina Toutanova  
*Proceedings of the 2019 Conference of the North* (2019) <https://doi.org/ggbwf6>  
DOI: [10.18653/v1/n19-1423](https://doi.org/10.18653/v1/n19-1423)

58. **PubMed Central: The GenBank of the published literature**  
Richard J Roberts  
*Proceedings of the National Academy of Sciences* (2001-01-16) <https://doi.org/bbn9k8>  
DOI: [10.1073/pnas.98.2.381](https://doi.org/10.1073/pnas.98.2.381) · PMID: [11209037](https://pubmed.ncbi.nlm.nih.gov/11209037/) · PMCID: [PMC33354](https://pubmed.ncbi.nlm.nih.gov/PMC33354/)
59. **Transformers: State-of-the-Art Natural Language Processing**  
Thomas Wolf, Lysandre Debut, Victor Sanh, Julien Chaumond, Clement Delangue, Anthony Moi, Pierric Cistac, Clara Ma, Yacine Jernite, Julien Plu, ... Alexander M Rush  
*Association for Computational Linguistics* (2020-10)  
<https://www.aclweb.org/anthology/2020.emnlp-demos.6>
60. **Adam: A Method for Stochastic Optimization**  
Diederik P Kingma, Jimmy Ba  
*arXiv* (2017-01-31) <https://arxiv.org/abs/1412.6980>
61. **Snorkel MeTaL: Weak Supervision for Multi-Task Learning**  
Alex Ratner, Braden Hancock, Jared Dunnmon, Roger Goldman, Christopher Ré  
*Proceedings of the Second Workshop on Data Management for End-To-End Machine Learning* (2018-06-15) <https://doi.org/gf3xk7>  
DOI: [10.1145/3209889.3209898](https://doi.org/10.1145/3209889.3209898) · PMID: [30931438](https://pubmed.ncbi.nlm.nih.gov/30931438/) · PMCID: [PMC6436830](https://pubmed.ncbi.nlm.nih.gov/PMC6436830/) · ISBN: 9781450358286
62. **A survey of transfer learning**  
Karl Weiss, Taghi M Khoshgoftaar, DingDing Wang  
*Journal of Big Data* (2016-12) <https://doi.org/gfkr2w>  
DOI: [10.1186/s40537-016-0043-6](https://doi.org/10.1186/s40537-016-0043-6)


## Supplemental Figures

---

### Generative Model Using Randomly Sampled Label Functions

#### Individual Sources

## Generative Model Performance for Predicted Relations (Test Set/AUPR)




**Figure 6:** Edge-specific label functions improve performance over edge-mismatch label functions. Each line plot header depicts the edge type the generative model is trying to predict, while the colors represent the source of label functions. For example, orange represents sampling label functions designed to predict the Compound treats Disease (CtD) edge type. The x-axis shows the number of randomly sampled label functions incorporated as an addition to the database-only baseline model (the point at 0). The y-axis shows the area under the precision-recall curve (AUPR). Each point on the plot shows the average of 50 sample runs, while the error bars show the 95% confidence intervals of all runs. The baseline and “All” data points consist of sampling from the entire fixed set of label functions.

## Collective Pool of Sources



## Generative Model Performance using All Label Functions (Test Set/AUPR)



**Figure 7:** Using all label functions generally hinders generative model performance. Each line plot header depicts the edge type the generative model is trying to predict, while the colors represent the source of label functions. For example, orange represents sampling label functions designed to predict the Compound treats Disease (CtD) edge type. The x-axis shows the number of randomly sampled label functions incorporated as an addition to the database-only baseline model (the point at 0). The y-axis shows the area under the precision-recall curve (AUPR). Each point on the plot shows the average of 50 sample runs, while the error bars show the 95% confidence intervals of all runs. The baseline and “All” data points consist of sampling from the entire fixed set of label functions.

## Discriminative Model Performance

Figure 10 displays four line plots showing the AUPR (Area Under the Precision-Recall Curve) performance of the Disc and Gen models across different numbers of Label Functions (LFs) added (0, 1, 6, 11, 16, All) for four different Relation (LF) Sources: CbG, CtD, DaG, and GiG. The y-axis represents AUPR, ranging from 0.2 to 0.5. The x-axis represents the Number of Label Functions Added.

Legend:

- Relation (LF) Source:
  - CbG (Blue)
  - CtD (Orange)
  - DaG (Green)
  - GiG (Pink)
- Model:
  - Disc (Solid line)
  - Gen (Dashed line)

Approximate AUPR values extracted from the plots:

| Relation (LF) Source | Model | 0    | 1    | 6    | 11   | 16   | All  |
|----------------------|-------|------|------|------|------|------|------|
| CbG                  | Disc  | 0.13 | 0.13 | 0.13 | 0.16 | 0.15 | 0.14 |
|                      | Gen   | 0.27 | 0.28 | 0.30 | 0.30 | 0.26 | 0.24 |
| CtD                  | Disc  | 0.34 | 0.34 | 0.35 | 0.38 | 0.40 | 0.38 |
|                      | Gen   | 0.30 | 0.31 | 0.35 | 0.37 | 0.43 | 0.47 |
| DaG                  | Disc  | 0.35 | 0.36 | 0.41 | 0.44 | 0.49 | 0.47 |
|                      | Gen   | 0.43 | 0.43 | 0.44 | 0.44 | 0.45 | 0.47 |
| GiG                  | Disc  | 0.21 | 0.24 | 0.26 | 0.28 | 0.29 | 0.31 |
|                      | Gen   | 0.31 | 0.30 | 0.30 | 0.29 | 0.29 | 0.28 |

## Supplemental Tables

**Table 3:** Contains the top ten predictions for each edge type. Highlighted words represent entities mentioned within the given sentence.

| Edge Type | Source Node | Target Node | Generative Model Prediction | Discriminative Model Prediction | Number of Sentences | In Hectonete | Text |
|-----------|-------------|-------------|-----------------------------|---------------------------------|---------------------|--------------|------|
|-----------|-------------|-------------|-----------------------------|---------------------------------|---------------------|--------------|------|

|     |                    |        |       |       |     |      |                                                                                                                                                                                                                                                                                                                                                                                          |
|-----|--------------------|--------|-------|-------|-----|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| DaG | hematologic cancer | STMN1  | 1.000 | 0.979 | 83  | None | the stathmin1 mrna expression level in de novo al patient be high than that in healthy person ( $p < 0.05$ ) , the [stathmin1].{gene_color} mrna expression level in relapse patient with al be high than that in de novo patient ( $p < 0.05$ ) , and there be no significant difference of stathmin1 mrna expression between patient with [aml].{disease_color} and patient with all . |
| DaG | breast cancer      | INSIG2 | 1.000 | 0.979 | 4   | None | in analysis of [idc ].{disease_color} cell , the level of [insig2].{gene_color} mrna expression be significantly high in late - stage patient than in early - stage patient .                                                                                                                                                                                                            |
| DaG | lung cancer        | GNAO1  | 1.000 | 0.979 | 104 | None | high [numb].{disease_color} expression be associate with favorable prognosis in patient with [lung adenocarcinoma].{gene_color} , but not in those with squamous cell carcinoma .                                                                                                                                                                                                        |
| DaG | breast cancer      | TTF1   | 1.000 | 0.977 | 88  | None | significant [ttf-1].{gene_color} overexpression be observe in adenocarcinomas harbor egfr mutation ( $p = 0.008$ ) , and no or significantly low level expression of ttf-1 be observe in [adenocarcinomas].{disease_color} harbor kras mutation ( $p = 0.000$ ) .                                                                                                                        |

|     |                                                                                   |                                      |           |           |             |                                      |                                                                                                                                                                                                                                                                                                                                                                                     |
|-----|-----------------------------------------------------------------------------------|--------------------------------------|-----------|-----------|-------------|--------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| DaG | b<br>r<br>e<br>a<br>s<br>t<br>c<br>a<br>n<br>c<br>e<br>r                          | B<br>U<br>B<br>1<br>B                | 1.0<br>00 | 0.97<br>7 | 1<br>3      | N<br>o<br>v<br>e<br>l                | elevated [bubr1].{gene_color} expression be associate with poor survival in early stage [breast cancer].{disease_color} patient .                                                                                                                                                                                                                                                   |
| DaG | A<br>l<br>z<br>h<br>e<br>i<br>m<br>e<br>r<br>s<br>d<br>i<br>s<br>e<br>a<br>s<br>e | S<br>E<br>R<br>P<br>I<br>N<br>A<br>3 | 1.0<br>00 | 0.97<br>7 | 1<br>8<br>2 | E<br>x<br>i<br>s<br>t<br>i<br>n<br>g | a common polymorphism within act and il-1beta gene affect plasma level of [act].{gene_color} or il-1beta , and [ad].{disease_color} patient with the act t , t or il-1beta t , t genotype show the high level of plasma act or il-1beta , respectively .                                                                                                                            |
| DaG | e<br>s<br>o<br>p<br>h<br>a<br>g<br>e<br>a<br>l<br>c<br>a<br>n<br>c<br>e<br>r      | T<br>R<br>A<br>F<br>6                | 1.0<br>00 | 0.97<br>6 | 1<br>5      | N<br>o<br>v<br>e<br>l                | expression of traf6 be highly elevated in [esophageal cancer].{disease_color} tissue , and patient with high [traf6].{gene_color} expression have a significantly short survival time than those with low traf6 expression .                                                                                                                                                        |
| DaG | h<br>y<br>p<br>e<br>r<br>t<br>e<br>n<br>s<br>i<br>o<br>n                          | T<br>B<br>X<br>4                     | 1.0<br>00 | 0.97<br>5 | 1<br>4<br>6 | N<br>o<br>v<br>e<br>l                | the proportion of circulate [th1].{gene_color} cell and the level of t - bet , ifng mrna be increase in [ht].{disease_color} patient , the expression of ifng - as1 be upregulated and positively correlate with the proportion of circulate th1 cell or t - bet , and ifng expression , or serum level of anti - thyroglobulin antibody / thyroperoxidase antibody in ht patient . |

|     |                   |                 |       |       |      |          |                                                                                                                                                                                                                                                                                                                                                                                  |
|-----|-------------------|-----------------|-------|-------|------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| DaG | breast cancer     | TP53            | 1.000 | 0.975 | 3481 | Existing | hormone receptor status rather than her2 status be significantly associate with increase ki-67 and [p53].{gene_color} expression in triple [- negative ]. {disease_color} breast carcinoma , and high expression of ki-67 but not p53 be significantly associate with axillary nodal metastasis in triple - negative and high - grade non - triple - negative breast carcinoma . |
| DaG | esophageal cancer | COL17A1         | 1.000 | 0.975 | 32   | None     | high [cd147].{gene_color} expression in patient with [esophageal cancer]. {disease_color} be associate with bad survival outcome and common clinicopathological indicator of poor prognosis .                                                                                                                                                                                    |
| CtD | docetaxel         | prostate cancer | 0.996 | 0.964 | 5614 | Existing | docetaxel and atrasentan versus [docetaxel ].{compound_color} and placebo for man with advanced castration - resistant [prostate cancer].{disease_color} ( swogs0421 ) : a randomised phase 3 trial                                                                                                                                                                              |
| CtD | E7389             | breast cancer   | 0.999 | 0.957 | 862  | None     | clinical effect of prior trastuzumab on combination [eribulin mesylate]. {compound_color} plus trastuzumab as first - line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic [breast cancer]. {disease_color} : result from a phase ii , single - arm , multicenter study                                                          |

|     |             |               |       |       |       |                                                                                                                                                                                                                                                                                                                                                             |
|-----|-------------|---------------|-------|-------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CtD | Zoledronate | bone cancer   | 0.996 | 0.955 | 226   | No [zoledronate].{compound_color} in combination with chemotherapy and surgery to treat [osteosarcoma].{disease_color} ( os2006 ) : a randomised , multicentre , open - label , phase 3 trial .                                                                                                                                                             |
| CtD |             |               | 0.878 | 0.954 | 484   | the role of [ixazomib].{compound_color} as an augment conditioning therapy in salvage autologous stem cell transplant ( asct ) and as a post - asct consolidation and maintenance strategy in patient with relapse multiple myeloma ( accord [ uk - mra [myeloma].{disease_color} xii ] trial ) : study protocol for a phase iii randomise controlled trial |
| CtD | Topotecan   | Lung cancer   | 1.000 | 0.954 | 315   | combine chemotherapy with cisplatin , etoposide , and irinotecan versus [topotecan].{compound_color} alone as second - line treatment for patient with [sensitive relapse small].{disease_color} - cell lung cancer ( jcog0605 ) : a multicentre , open - label , randomised phase 3 trial .                                                                |
| CtD | Epirubicin  | breast cancer | 0.999 | 0.953 | 2147  | accelerate versus standard [epirubicin].{compound_color} follow by cyclophosphamide , methotrexate , and fluorouracil or capecitabine as adjuvant therapy for [breast cancer].{disease_color} in the randomised uk tact2 trial ( cruk/05/19 ) : a multicentre , phase 3 , open - label , randomise , control trial                                          |
| CtD | Paclitaxel  | breast cancer | 1.000 | 0.952 | 10255 | sunitinib plus [paclitaxel].{compound_color} versus bevacizumab plus paclitaxel for first - line treatment of patients with [advanced breast cancer].{disease_color} : a phase iii , randomized , open - label trial                                                                                                                                        |



|     |                  |                 |       |       |       |            |                                                                                                                                                                                                                                                                                                               |
|-----|------------------|-----------------|-------|-------|-------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CtD | Anastrozole      | breast cancer   | 0.996 | 0.952 | 2364  | Exits in g | a european organisation for research and treatment of cancer randomize , double - blind , placebo - control , multicentre [phase].{disease_color} ii trial of anastrozole in combination with [gefitinib or placebo in hormone].{compound_color} receptor - positive advanced breast cancer ( nct00066378 ) . |
| CtD | Gefitinib        | Lung cancer     | 1.000 | 0.950 | 11860 | Exits in g | [gefitinib].{compound_color} versus placebo as maintenance therapy in patient with locally advanced or metastatic [non - small].{disease_color} - cell lung cancer ( inform ; c - tong 0804 ) : a multicentre , double - blind randomise phase 3 trial .                                                      |
| CtD | Docetaxel        | prostate cancer | 1.000 | 0.949 | 5614  | Exits in g | ipilimumab versus placebo after radiotherapy in patient with metastatic castration - resistant [prostate cancer].{disease_color} that have progress after [docetaxel].{compound_color} chemotherapy ( ca184 - 043 ) : a multicentre , randomised , double - blind , phase 3 trial                             |
| CtD | Sulfamethoxazole | Lung cancer     | 0.611 | 0.949 | 4     | No veil    | [tmp].{compound_color} / smz ( 320/1600 mg / day ) treatment be compare to placebo in a double - blind , randomized trial in [patient with newly diagnose].{disease_color} small cell carcinoma of the lung during the initial course of chemotherapy with cyclophosphamide , doxorubicin , and etoposide .   |
| CbG | D-Tyrosine       | EGFR            | 0.601 | 0.876 | 3423  | No veil    | amphiregulin ( ar ) and heparin - binding egf - like growth factor ( hb - [egf].{gene_color} ) bind and activate the egfr while heregulin ( hrg [] act ].{compound_color} through the p185erbb-2 and p180erbb-4 tyrosine kinase .                                                                             |

|     |                                                                                   |                       |           |           |             |                       |                                                                                                                                                                                                                                                                                        |
|-----|-----------------------------------------------------------------------------------|-----------------------|-----------|-----------|-------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CbG | P<br>h<br>o<br>s<br>p<br>h<br>o<br>n<br>o<br>t<br>y<br>r<br>o<br>s<br>i<br>n<br>e | A<br>N<br>K<br>3      | 0.0<br>04 | 0.86<br>5 | 1           | N<br>o<br>v<br>e<br>l | at least two domain of p85 can bind to [ank3 ].{gene_color} , and the interaction involve the p85 c - sh2 domain be find to be [phosphotyrosine].{compound_color} - independent .                                                                                                      |
| CbG | A<br>d<br>e<br>n<br>o<br>s<br>i<br>n<br>e                                         | A<br>B<br>C<br>C<br>8 | 0.8<br>91 | 0.86<br>0 | 3<br>5<br>3 | N<br>o<br>v<br>e<br>l | sulfonylurea act by inhibition of [beta - cell ].{compound_color} adenosine triphosphate - dependent potassium ( k(atp ) ) channel after bind to the sulfonylurea subunit 1 [receptor ( ].{gene_color} sur1 ) .                                                                        |
| CbG | D<br>-<br>T<br>y<br>r<br>o<br>s<br>i<br>n<br>e                                    | A<br>R<br>E<br>G      | 0.8<br>91 | 0.85<br>7 | 2<br>2      | N<br>o<br>v<br>e<br>l | amphiregulin ( [ar ] ).{gene_color} and heparin - binding egf - like growth factor ( hb - egf ) bind and activate the egfr while heregulin ( hrg [] act ].{compound_color} through the p185erbb-2 and p180erbb-4 tyrosine kinase .                                                     |
| CbG | D<br>-<br>T<br>y<br>r<br>o<br>s<br>i<br>n<br>e                                    | E<br>G<br>F           | 0.6<br>02 | 0.85<br>6 | 3<br>8<br>9 | N<br>o<br>v<br>e<br>l | upon activation of the receptor for the epidermal growth factor ( [egfr ] ). {gene_color} , sprouty2 undergoe phosphorylation at a conserve [tyrosine ]. {compound_color} that recruit the src homology 2 domain of c - cbl .                                                          |
| CbG | D<br>-<br>T<br>y<br>r<br>o<br>s<br>i<br>n<br>e                                    | C<br>S<br>F<br>1      | 0.1<br>01 | 0.85<br>4 | 1<br>0<br>6 | N<br>o<br>v<br>e<br>l | as a member of the subclass iii family of receptor [tyrosine].{compound_color} kinase , kit be closely relate to the receptor for platelet derive growth factor alpha and beta ( pdgf - a and b [] , macrophage colony ].{gene_color} stimulate factor ( m - csf ) , and flt3 ligand . |

|     |                |         |       |       |      |    |                                                                                                                                                                                                                                                                                                                            |
|-----|----------------|---------|-------|-------|------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CbG | D - Tyrosine   | ERBB4   | 0.101 | 0.848 | 115  | No | the efgr family be a group of four structurally similar [tyrosine ].{compound_color} kinase ( egfr , her2 / neu , erbb-3 [, and erbb-4].{gene_color} ) that dimerize on bind with a number of ligand , include egf and transform growth factor alpha .                                                                     |
| CbG | D - Tyrosine   | EGFR    | 0.969 | 0.848 | 3423 | No | the [epidermal growth factor receptor ].{gene_color} be a member of type - -pron-growth factor receptor [family ].{compound_color} with tyrosine kinase activity that be activate follow the binding of multiple cognate ligand .                                                                                          |
| CbG | D - Tyrosine   | VAV1    | 0.601 | 0.842 | 187  | No | stimulation of quiescent rodent fibroblast with either epidermal or platelet - derive growth factor induce an increase affinity of vav for cbl - b and result in the [subsequent ].{gene_color} formation of a vav - [dependent ].{compound_color} trimeric complex with the ligand - stimulate tyrosine kinase receptor . |
| CbG | Retinoid       | RORB    | 0.601 | 0.840 | 7    | No | the retinoid z receptor beta ( [rzt beta ) ].{gene_color} , an orphan receptor , be a member of the [retinoic acid].{compound_color} receptor ( rar)/thyroid hormone receptor ( tr ) subfamily of nuclear receptor .                                                                                                       |
| CbG | L - Tryptophan | TACR1   | 0.891 | 0.839 | 4    | No | these result suggest that the [tryptophan ].{compound_color} and quinuclidine series of nk-1 antagonist bind to similar bind site on the human [nk-1 receptor ].{gene_color} .                                                                                                                                             |
| GiG | CYSLTR2        | CYSLTR2 | 0.967 | 0.564 | 37   | No | the bind pocket of [cyslt2 ].{gene2_color} receptor and the proposition of the interaction mode between [cyslt2 ].{gene1_color} and hami3379 be identify .                                                                                                                                                                 |

|     |                            |                            |           |           |                  |                                      |                                                                                                                                                                                                                                                                                                                                                           |
|-----|----------------------------|----------------------------|-----------|-----------|------------------|--------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| GiG | R<br>X<br>R<br>A           | P<br>P<br>A<br>R<br>A      | 1.0<br>00 | 0.56<br>3 | 1<br>4<br>3      | N<br>o<br>v<br>e<br>l                | after bind ligand , the [ppar ].{gene2_color} - y receptor heterodimerize [with ].<br>{gene1_color} the rxr receptor .                                                                                                                                                                                                                                    |
| GiG | R<br>X<br>R<br>A           | R<br>X<br>R<br>A           | 0.8<br>24 | 0.55<br>1 | 1<br>1<br>0<br>1 | E<br>x<br>i<br>s<br>t<br>i<br>n<br>g | nuclear hormone receptor , for example , bind either as homodimer or as heterodimer with [retinoid x receptor ].{gene1_color} ( [rxr ) ].{gene2_color} to half - site repeat that be stabilize by protein - protein interaction mediate by residue within both the dna- and ligand - bind domain .                                                        |
| GiG | A<br>D<br>R<br>B<br>K<br>1 | A<br>D<br>R<br>A<br>2<br>A | 0.8<br>22 | 0.54<br>3 | 3                | N<br>o<br>v<br>e<br>l                | mutation of these residue within the [holo - alpha(2a)ar diminish grk2-promoted].<br>{gene2_color} phosphorylation [of ].{gene1_color} the receptor as well as the ability of the kinase to be activate by receptor binding .                                                                                                                             |
| GiG | E<br>S<br>R<br>R<br>A      | E<br>S<br>R<br>R<br>A      | 0.0<br>01 | 0.53<br>1 | 3<br>0<br>8      | E<br>x<br>i<br>s<br>t<br>i<br>n<br>g | the crystal structure of the ligand bind domain ( lbd ) of the estrogen - relate receptor [alpha ].{gene2_color} ( [erralpha , ].{gene1_color} nr3b1 ) complexe with a coactivator peptide from peroxisome proliferator - activate receptor coactivator-1alpha ( pgc-1alpha ) reveal a transcriptionally active conformation in the absence of a ligand . |
| GiG | G<br>P<br>1<br>B<br>A      | V<br>W<br>F                | 0.5<br>18 | 0.52<br>7 | 1<br>4<br>4      | E<br>x<br>i<br>s<br>t<br>i<br>n<br>g | these finding indicate the novel bind site require for [vwf ].{gene2_color} binding of human [gpibalpha ].{gene1_color} .                                                                                                                                                                                                                                 |
| GiG | N<br>R<br>2<br>C<br>1      | N<br>R<br>2<br>C<br>1      | 0.0<br>27 | 0.52<br>2 | 2<br>6           | N<br>o<br>v<br>e<br>l                | the human [testicular receptor 2].{gene1_color} ( [tr2 )].{gene2_color} , a member of the nuclear hormone receptor superfamily , have no identify ligand yet .                                                                                                                                                                                            |
| GiG | N<br>C<br>O<br>A<br>1      | E<br>S<br>R<br>R<br>G      | 0.9<br>92 | 0.51<br>8 | 1                | N<br>o<br>v<br>e<br>l                | the crystal structure of the ligand bind domain ( lbd ) of the estrogen - relate receptor [3 (].{gene2_color} err3 ) complexe with a steroid receptor [coactivator-1 (].{gene1_color} src-1 ) peptide reveal a transcriptionally active conformation in absence of any ligand .                                                                           |
| GiG | P<br>P<br>A<br>R<br>G      | P<br>P<br>A<br>R<br>G      | 0.8<br>24 | 0.50<br>4 | 2<br>4<br>9<br>7 | E<br>x<br>i<br>s<br>t<br>i<br>n<br>g | although these agent can bind and activate an orphan nuclear receptor ,<br>[peroxisome proliferator - activate].{gene2_color} receptor [gamma ( ].<br>{gene1_color} ppargamma ) , there be no direct evidence to conclusively implicate this receptor in the regulation of mammalian glucose homeostasis .                                                |

|     |       |       |       |       |      |          |                                                                                                                                                                                                 |
|-----|-------|-------|-------|-------|------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| GiG | ESR2  | ESR1  | 0.995 | 0.503 | 1715 | Novel    | ligand bind experiment with purify [er alpha].{gene2_color} and [er beta].{gene1_color} confirm that the two phytoestrogen be er ligand .                                                       |
| GiG | FGFR2 | FGFR2 | 1.000 | 0.501 | 584  | Existing | receptor modeling of [kgfr].{gene1_color} be use to identify selective kgfr tyrosine kinase ( tk ) inhibitor molecule that have the potential to bind selectively to the [kgfr].{gene2_color} . |